|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Bartter's syndrome:clinical findings,genetic causes and therapeutic approach显示文摘Backgound Bartter's syndrome(BS)is a rare group of salt losing tubulopathies due to the impairment of transport mecha-nisms at the thick ascending limb of the Henle's loop.Data sources Literature reviews and original research articles were collected from database,including PubMed and Scopus.Results According to the time of onset and symptoms,BS can be classified into antenatal and classic BS.Molecular studies have identified different subtypes of BS.BS types Ⅰ,Ⅱ and Ⅲ are caused by mutations on genes encoding the luminal Na^(+)-K^(+)-2Cl^(-) co-transporter,the luminal K+ channel ROMK,and the basolateral chloride channel ClC-Kb(CLCNKB),respectively.Loss-of-function mutations of Barttin CLCNK type accessory beta subunit cause BS type Ⅳa.Simultaneous mutations of CLCNKB and CLCNKA cause BS type Ⅳb.BS type Ⅴ consists in a novel transient form characterized by antenatal presentation due to mutations in the MAGE family member D2.Severe gain-of-function mutations of the extracellular calcium sensing receptor gene can result in an autosomal dominant condition of BS.Main clinical and biochemical alterations in BS include polyuria,dehydration,hypokalemia,hypochloremic metabolic alka-losis,hyperreninemia,high levels of prostaglandins,normal or low blood pressure,hypercalciuria and failure to thrive.Treatment focuses mainly at correcting dehydration and electrolyte disturbances and in measures to reduce polyuria,including the use of nonsteroidal anti-inflammatory medications to control excessive renal prostaglandin E2 production.Conclusions Early diagnosis and treatment of BS may prevent long-term consequences such as growth failure,nephrocal-cinosis and end-stage renal disease. | Flavia Cristina Carvalho Mrad Sílvia Bouissou Morais Soares Luiz Alberto Wanderley de Menezes Silva Pedro Versiani dos Anjos Menezes Ana Cristina Simoes-e-Silva | 2021 | World Journal of Pediatrics2021，17，1： | 10 |
| 2 | GC/GCMS analysis of the petroleum ether and dichloromethane extracts of Moringa oleifera roots显示文摘Objective:To explore the phytochemical constituents from petroleum ether and diehloromethane extracts of Moringa oleifera(M.oleufera)roots using GC/GC—MS.Methods:A total of 5.11 kg fresh and undried crashed root of M.oleifera were cut into small pieces and extracted with petroleum ether and diehloromethane(20 L.each) at room temperature for 2 d.The concentrated extracts were subjected to their GC—MS analysis.Results:The GC-MS analysis of the petroleum ether and diehloromethane extracts of M.oleifern roots,which showed promising biological activities,has resulted in the identification 102 compounds.These constituents belong to 15 classes of compounds including hydrocarbons,fatty acids,esters,alcohols,isolhioeyanate.thiocyanale,pyrazine,aromalics.alkamides.cyanides,steroids,halocompounds.urea and N-hydroxyimine derivatives,unsaturated alkenamides.alkyne and indole.GC/GC-MS studies on petroleum ether extraet of the roots revealed that it contained 39 compounds,belonging to nine classes.Cyclooctasulfur S8 has been isolated as a pure compound from the extract.The major compounds identified from petroleum ether extract were trans-13-clocosene(37.9%).nonacosane(32.6%).cycloartenol(28.6%) nonadecanoic acid(13.9%) and cyclooctasulfur S8(13.9%).Dichloromethane extract of the roots was composed of 63 compounds of which nasimizinol(58.8%) along with oleic acid(46.5%),N—benzyl-N-(7—cyanato heptanamide(38.3%),N—benzyl-N—(1—chlorononyl) amide(30.3%),bis[3—benzyl prop-2-ene]-1-one(19.5%) and N.N-dibeuzyl—2-ene pent 1.5—diamide(11.6%) were the main constituents.Conclusions:This study helps to predict the formula and structure of active molecules which can be used as drugs.This result also enhances the traditional usage of M.oleifera which possesses a number of bioactive compounds. | Shaheen Faizi saima sumbul Muhammed Ali Versiani Rubeena Saleem Aisha Sana Hira Siddiqui | 2014 | Asian Pacific Journal of Tropical Biomedicine2014，4，8： | 2 |
| 3 | Clinical management and subsequent healing of teeth with horizontal root fractures 显示文摘 | Versiani MA de Sousa C J Cruz-Filho AM | 2008 | Dent Traumatol2008，24，1： | 1 |
| 4 | Computed systems on the root canal transportation and centering ability 显示文摘 | Paghosa A Sousa-Neto MD Versiani MA | 2015 | Braz Oral Res2015，29，1： | 1 |
| 5 | Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well -tolerated treatment for panic disorder显示文摘 | Savino M Versiani M Cassano G | 2002 | J Clin Psychiat2002，63，： | 1 |
| 6 | A comparative study of physicochemical properties of AH plus, epiphany, and Epiphany SE root canal sealers显示文摘 | Resende LM Rached-Junior FJ Versiani MA | 2009 | Int EndodJ2009，42，9： | 1 |
| 7 | Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized Trial 显示文摘 | KECK PE VERSIANI M POTKIN S | 2003 | Am J Psychiatry2003，160，4： | 1 |
| 8 | Double - blind, placebo - controlled study with reboxetine in inpatients with severe major depressive disorder 显示文摘 | Versiani M Amin M Chouinard G | 2000 | Clin Psychopharmacol2000，20，： | 1 |
| 9 | Ziprasidone in bipolar disorder显示文摘 | VERSIANI M | 2006 | Expert Opin Pharmacother2006，7，9： | 1 |
| 10 | Ziprasidone in the treatment of acute bipolarmaniaz a three--week placebo--controlled, double--blind, randomized trial显示文摘 | Keck PE Jr Versiani M Potkin S | 2003 | Am J Psychiatry2003，160，： | 1 |
| 11 | Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial显示文摘 | VERSIANI M AMREIN R STABL M | 1997 | Int Clin Psychopharmacol1997，12，4： | 1 |
| 12 | Correla- tive Bacteriologic and Micro-Computed Tomographie Analy- sis of Mandibular Molar Mesial Canals Prepared by Self- Ad- justing File, Reeiproe, and Twisted File Systems 显示文摘 | Siqueira Jr J F Aires F R F Versiani M A | 2013 | Jour- nal of endodonties2013，39，8： | 1 |
| 13 | Moclobemine and imipramine in chronic depression (dystymia):an international collaborative study group显示文摘 | Versiani M Amerin R Stab1 M | 1997 | Int Clin Psychopharmacal1997，12，4： | 1 |
| 14 | Pharmacotherapy of social phobia:controlled study with moclobemide and phenelzine显示文摘 | Versiani M Nardi AE Mundim FD | 1992 | Br J Psychiatry1992，161，： | 1 |
| 15 | Group cognitive behavior therapy for bipolar disorder can improve the quality of life 显示文摘 | Costal RT Cheniaux E Versiani M | 2012 | Braz J Med Biol Res2012，45，： | 1 |
| 16 | The descriptive epidemiology of obsessive - compulisive disorder 显示文摘 | Fontenelle LF Mendlowicz MV Versiani M | 2006 | Proeuro psychopharm aool & Biol Psych iatary2006，30，3： | 1 |
| 17 | A compara- tive study of physicochemical properties of AH Plus,Epiphany, and Epiphany SE root canal sealers显示文摘 | Resende LM Rached-Junior F J Versiani MA | 2009 | Int Endod J2009，42，9： | 1 |
| 18 | Ziprasidone in the treatment of acute bipolar mania: a three- week, placebo- controlled, double - blind, randomized trial 显示文摘 | Keck PEJ Versiani M Potkin S | 2003 | Am J Psychiatry2003，160，4： | 1 |
| 19 | Clinical assessment and molecular analysis of GnRHR and KAL1 genes in males with idiopathic hypogonadotrophic hypogonadism显示文摘 | Versiani BR Trarbach E Koenigkam-Santos M | 2007 | Clin Endocrinol(Oxf)2007，66，2： | 1 |
| 20 | Kallmann syndrome and mirror movements:White matter quantitative evaluation with magnetic resonance imaging显示文摘 | Koenigkam-Santos M de Castro M Versiani BR | 2010 | J Neurol Sci2010，292，12： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员